Virus-specific ligands: How to find the 'unchanging' parts on ever-mutating viruses?

Viruses are the most streamlined 'molecular machines' in nature. They have no legs and can’t move toward a target on their own; they have no brain and can’t decide which tissue to attack. Yet, a respiratory virus mainly targets the respiratory epithelial cells, while a hepatitis virus seems to have a special preference just for the liver. Behind this amazing specificity lies a molecular-level 'code system'—the proteins on the virus surface act like a key, fitting precisely into receptors on the host cell surface. That moment when the 'key inserts into the lock' marks the beginning of infection.

Conversely, if we can block the virus's 'key' with a molecule before it contacts the cell, preventing it from 'unlocking' the cell, the infection won’t happen. Molecules that can specifically recognize and bind viruses are called virus-specific ligands. They can be antibodies, soluble receptors, peptides, or even nucleic acid aptamers. From early serum therapy to modern monoclonal antibody drugs, from neutralizing antibodies induced by vaccines to capture antibodies in diagnostic tests, virus-specific ligands have always been one of the core tools in the fight against viruses.

1. One 'key,' three challenges

The concept of a virus-specific ligand is clear, but designing a good one is incredibly difficult. Viruses mutate far faster than antiviral drugs or vaccines can keep up—flu viruses drift every year, COVID variants appear within months, and HIV is one of the highest mutating RNA viruses, forming highly complex viral quasispecies within the host. A ligand with high affinity today might be outflanked by a variant tomorrow. Finding something 'unchanging' in a constantly mutating virus is the eternal engineering challenge in this field.

Three Core Challenges

This tough problem is made up of three overlapping challenges.

The first is the risk of escape. The virus's RNA polymerase or reverse transcriptase lacks a proofreading mechanism, so the mutation rate is extremely high. HIV introduces roughly 10⁻⁵ mutations per base per replication cycle, which works out to about 0.1 new mutations per full genome each time it replicates. Coupled with a very high replication rate (about 10¹⁰ particles per day) and continuous accumulation of mutations, the viral population in an infected person can cover almost all possible single-point mutations within just a few weeks. Antibody drugs can remain effective in the body for several weeks, during which the virus keeps replicating and accumulating mutations, making it highly likely that variants capable of escaping antibody detection will appear. If antibodies target regions of the virus that are prone to mutation, escape can happen during treatment. That's why antiviral antibody drugs usually use a cocktail strategy—combining multiple antibodies targeting different epitopes to reduce the chance that a single escape will make the treatment ineffective.

The second is conformational dynamics. Viral surface proteins—like the coronavirus spike protein, influenza hemagglutinin, or HIV Env—aren't static targets. They switch between open and closed conformations, and between pre-fusion and post-fusion states. An antibody targeting one conformation may bind very weakly to another. Adding to the complexity, many broadly neutralizing antibodies recognize a 'fusion intermediate' conformation, which only exists briefly at the moment the virus fuses with the cell membrane and is present in tiny amounts on the viral surface. Screening for ligands that target these fleeting conformations is an engineering challenge in itself.

The third is the glycosylation barrier. Many viral surface proteins are covered by a dense layer of glycosylation. The sugar density on HIV Env is among the highest of all known viral envelope proteins, making up almost half of the extracellular domain's molecular weight. This creates a 'glycan shield' that hides most of the protein's surface, making it hard for antibodies to reach. They can only find targets in the gaps between glycans, which tend to be highly dynamic and often immunologically suboptimal epitopes. Glycosylation not only makes ligand discovery harder but also complicates recombinant expression—different expression systems produce different glycosylation patterns, which can affect the protein's conformation and how epitopes are displayed.

These three challenges together mean that developing virus-specific ligands isn’t just about 'finding a binder.' It's about finding a stable and lasting molecular solution amidst the triple barriers of mutation, conformational dynamics, and glycosylation.

2. Three Routes, Three Strategies to Outwit Viruses

Faced with these three challenges, the development of virus-specific ligands generally follows three technical routes. There’s no single “best solution”—which path to take depends on the virus’s mutation rate, how conserved the target is, and the timeframe of the project.

Three Development Approaches

Strain-specific neutralizing antibodies: a "direct borrow" of the immune system. This is the classic approach—isolating monoclonal antibodies from the serum of recoveries, binding the viral surface protein with high affinity and blocking its interaction with the host receptor. Its advantages are high affinity, strong specificity, and clear mechanism of action. During the COVID-19 pandemic, several neutralizing antibody drugs advanced from discovery to emergency use authorization within a year, demonstrating the maturity of this technological route. However, the biggest weakness of these neutralizing antibodies is their narrow spectrum—most monoclonal antibodies only recognize a single strain, and the virus may escape once a key site mutates. The emergence of the Omicron variant and the loss of multiple neutralizing antibodies is a harsh footnote to this limitation.

Soluble receptors: use the virus's own "lock" as ligands. Since viruses must bind to host receptors to invade, turning the extracellular domain of the receptor into soluble "bait receptors" can competitively "lure" the virus. ACE2-Fc fusion protein is a product of this approach. The advantage of soluble receptors lies in their targeting conserved regions within the viral receptor-binding domain that interact with natural receptors—for the virus to escape, it must alter its receptor-binding capacity, which often reduces the virus's own adaptability. The disadvantage is that the affinity of natural receptors is usually inferior to antibodies matured by affinity, and additional engineering modifications may be required to achieve therapeutic efficacy.

Broad-spectrum neutralizing antibodies: Seek constancy among variations. Within the same antibody route, broad-spectrum neutralizing antibodies take a differentiated path: their approach is to lock onto conserved regions on the virus surface that are resistant to mutation—core sites for receptor binding, key conformations for membrane fusion mechanisms, and conserved regions with less glycosylation masking—and develop antibodies for these regions. Some broad-spectrum HIV neutralizing antibodies can neutralize multiple subtypes of the virus, while some influenza broad-spectrum neutralizing antibodies can cover multiple hemagglutinin subtypes. However, detection is also extremely difficult: these antibodies usually target immune subdominant epitopes and require longer periods of affinity maturation, making it difficult for conventional immunization or screening methods to effectively enrich these antibodies.

3. MatwingsVenus™ Intelligent Agent: From "Taking a Chance" to "Having Direction"

The development of traditional virus-specific ligands heavily relies on a "large library with multiple rounds of screening"—using a sufficiently large diversity library to try their luck. However, when facing viral targets with high mutation rates, complex conformations, and dense glycosylation, screening efficiency is the key to success. The capability combination of the MatwingsVenus™ (Xiaowu ™) agent provides directional guidance for ligand development before screening.

MatwingsVenus™

Computational identification of conserved epitopes. The premise of broad-spectrum neutralizing antibodies is finding epitopes that are both conserved and functional. The MatwingsVenus™ (Xiaowu™) AI agent can systematically analyze conserved regions on the viral surface protein across different strains and subtypes through multiple sequence alignment and structural prediction. It can also annotate which conserved regions are associated with key functions like receptor binding or membrane fusion. This information allows researchers to pinpoint “high-value targets” before screening begins, focusing on conserved epitopes instead of blindly screening the entire protein.

Structural simulation of conformational dynamics. For highly dynamic viral envelope proteins, structural prediction can help evaluate how ligands bind to different conformational states—do they prefer the pre-fusion closed state or a fusion intermediate? Will binding induce conformational changes? It’s worth noting that the transient fusion intermediate state is still challenging for structural prediction, and results need experimental verification. Structural prediction can also aid in designing conformation-locked antigens for screening ligands that target specific conformations.

Pre-assessment of mutation escape risk. Once candidate ligand sequences are determined, the MatwingsVenus™ (Xiaowu™) AI agent can use complex structure models to predict which interface residues are most likely to lead to escape mutations—are these escape mutations already present in known variant databases? This pre-assessment helps identify high-risk candidate ligands early in development, prioritize ligands targeting conserved sites, or plan cocktail strategies ahead of time.

Computational methods can’t replace experiments, but they can turn a “needle in a haystack” screening into a targeted search in high-probability regions. When viruses mutate faster than screens can keep up, doing predictions and design on the computer first, then validating in the lab, is another way to gain a time advantage.

Conclusion

Developing virus-specific ligands is an endless arms race. Viruses mutate, and ligand development technology evolves—from early serum therapies to monoclonal antibodies, from single antibodies to cocktail combinations, from immune-based screening to computationally assisted design. Each technological advance gives us more control in the race against viral mutation.

The role of the MatwingsVenus™ (Xiaowu™) AI agent in this race is to make the starting direction more precise. When conserved epitopes can be systematically identified, when conformational dynamics can be simulated, and when escape risk can be predicted in advance—the development of viral ligands shifts from a game of “luck” to a guided process.

Viruses will continue to mutate; it’s part of their survival strategy. But “finding the unchanging within the changing” is turning from a scientific ideal into a computable, verifiable engineering methodology.